Management of In-transit Disease: Regional Therapies, Intralesional Therapies, and Systemic Therapy.

Margaret H O'Connor, Kristen E Rhodin, Douglas S Tyler, Georgia M Beasley

Abstract readReview

In one paragraph

Review in Surgical oncology clinics of North America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Margaret H O'ConnorDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Kristen E RhodinDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Douglas S TylerDepartment of Surgery, Texas Medical Branch, Galveston, TX, USA.

Georgia M BeasleyDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: Georgia.beasley@duke.edu.

Funding

PVSRIPO in melanomaK08CA237726 · NCI · DUKE UNIVERSITY · PI BEASLEY, GEORGIA · 2020 to 2024

$1.0M

NCI NIH HHS K08 CA237726

6 · The paper itself

Abstract

In-transit (IT) melanoma represents a distinct, heterogeneous pattern of disease that arises as superficial tumors along the track between the primary site and the draining regional lymph node basin. Many therapies have been explored for treatment of this disease with the goal of maximizing delivery of the therapeutic agent to the tumor while minimizing systemic toxicities. These include regional chemotherapies, intralesional injections, checkpoint inhibitors, immunomodulators, and vaccines in various combinations or as monotherapy. Here, we review the general managemnt of patients with ITmelanoma, the range of currently available treatment options, and recommendations for specific therapies for individual patients.

Indexed as

MelanomaSkin NeoplasmsDisease ManagementHumansImmunotherapyInjections, IntralesionalImmunotherapyIntralesional therapyIn-transit melanomaRegional therapy

Identifiers

PMID40413006

DOI10.1016/j.soc.2024.11.004

PMCPMC12104569

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.